Connect with us

National

Single-shot Johnson & Johnson vaccine 66 per cent effective against COVID-19, study shows – Sydney Morning Herald

The company says its vaccine is 72 per cent effective in preventing COVID-19 in the US but a lower rate of 66 per cent was observed globally in the large trial…

Published

on

That level of prevention will potentially protect hundreds of millions of people from serious and fatal outcomes of COVID-19, Dr Paul Stoffels, J&Js chief scientific officer, said in a statement.
The company plans to seek emergency use authorisation from the US Food and Drug Administration next week.
Public health officials have been counting on the J&J vaccine to increase much-needed supply and simplify the US immunisation campaign.
Unlike the Pfizer/BioNTech and Moderna vaccines, J&Js does not…

Click here to view the original article.